TrialCancer2019

Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma.

Lynn G Feun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.